IASO206 cell therapy for hard-to-treat autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old with diagnosed autoimmune hemolytic anemia or Evans syndrome that has not responded to multiple treatments
- Your red blood cell count must be low (hemoglobin < 10 g/dL) and you must have tried at least 2 immunosuppressive drugs, including a CD20 monoclonal antibody (like Rituximab), and taken steroids for at least 3 months
- Your heart, liver, and kidney function must be adequate based on blood tests and heart imaging
- You cannot have had a recent heart attack, organ transplant, cancer, or uncontrolled infection
- You must agree to use reliable birth control for 1 year after treatment and be willing to provide written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This trial tests a new cell therapy (YTS109) for people with autoimmune hemolytic anemia (AIHA) that has not responded to at least three prior treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new drug called enatumab for people with warm antibody autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two prior treatments. The goal is to see if enatumab can help control the disease.
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.